Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 1158 results for "ranbaxy"

Ranbaxy Launches Acne Treatment Capsules in US
NDTV

Ranbaxy launches ABSORICA in the US market

Is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older Ranbaxy Laboratories has launched ABSORICA (isotretinoin) 25 mg and 35 mg capsules into the US healthcare market. ABSORICA has become the most ... Express Pharma, 16 hours ago
Ranbaxy launches acne treatment capsules in the US market Business Standard India, 16 hours ago
[x]  

640 images for ranbaxy

NDTV, 11 hours ago
Sify, 1 week ago
Livemint.com, 9 hours ago
NDTV Profit, 1 week ago
Livemint.com, 1 week ago
Reuters India, 1 week ago
Yahoo! News, 1 week ago
Money Control, 1 week ago
Livemint.com, 1 week ago
Business Today India, 1 week ago

Angel Broking maintains ''Neutral'' on Sun Pharma

Sun Pharmaceuticals plans to focus on dermatology, post its merger with Ranbaxy Labs, expected to be completed by 2014. The company has lined-up a strategy to make dermatology its biggest segment and expects almost 38-40% of US sales to come from ...
 MyIris2 days ago Sun Pharma to focus on dermatology post merger with Ranbaxy  Money Control2 days ago Angel Broking neutral on Ranbaxy Laboratories  Money Control1 month ago

Buy Asian Paints, Titan, Ranbaxy: Vishal Malkan

Vishal Malkan of malkansview.com recommends buying Asian Paints, Titan Company and Ranbaxy Laboratories.
 Money Control2 days ago Bull's Eye: Buy Siemens, Crompton, NBCC, Ranbaxy, Biocon  Money Control2 weeks ago Super Six buy or sell calls for September 18  Money Control2 weeks ago Buy Ranbaxy; sell Rel Cap, CESC, Adani Ent: Meghana Malkan  Money Control2 weeks ago
Rediff.com

Benefit of Ranbaxy deal to accrue in few years: Sun Pharma

It will take a ‘few years’ for Sun Pharma to realise the benefits of its $4 billion takeover of Ranbaxy, said the company's Chairman Israel Makov, terming the deal as a ‘complex and large acquisition’. Sun will leverage on complementary functional strengths to achieve topline growth and gains through both revenue enhancement and operational synergies, translating into higher margins, greater market share and more profits through the takeover of Ranbaxy, he said. "Ranbaxy ...
 Rediff.com2 days ago Sun-Ranbaxy Deal: CCI Public Scrutiny Deadline Ends  Outlook1 week ago Sun Pharma-Ranbaxy deal: CCI's deadline ends today  Economic Times1 week ago Sun Pharma-Ranbaxy deal: CCI's public scrutiny deadline ends today  Economic Times1 week ago
[x]  

Ranbaxy Laboratories' Q2 results on October 28, 2014

Ranbaxy Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on October 28, 2014, inter alia, to consider and approve Standalone and Consolidated Unaudited Financial Results for the second quarter and half ...
 Money Control2 days ago Ranbaxy Laboratories: Outcome of court convened meeting of equity shareholders  Money Control1 week ago Ranbaxy Labs' court convened meeting on Sept 19, 2014  Money Control1 month ago

Buy Ranbaxy with a target of Rs 650: Sandeep Wagle

In a chat with ET Now, Sandeep Wagle, Founder & CEO, Power My Wealth, shares his views on Ranbaxy. ET Now: What is your call on Ranbaxy? Sandeep Wagle: Ranbaxy is a 'BUY' call with a target of Rs 650 and a stop loss of
 Economic Times3 days ago Buy Ranbaxy with a target of Rs 680: Prakash Gaba  Economic Times4 weeks ago Buy Ranbaxy with a target of Rs 589: Prakash Gaba  Economic Times1 month ago Buy Ranbaxy with a target of Rs 618: Sandeep Wagle  Economic Times1 month ago

CNX Pharma at record high; Sun, Ranbaxy on roll

Among the top performers in the pharma space have been Sun Pharmaceuticals, Ranbaxy, Lupin and Aurobindo Pharmaceuticals. MUMBAI: The momentum is building up in pharmaceutical companies ahead of the second quarter earnings. Investors are ditching cyclicals ...
 Economic Times2 days ago CNX Pharma at record high; Sun Pharma, Ranbaxy on roll  Economic Times2 days ago

1,800 companies legal spend up 18% to $3.5bn - RIL alone billed Rs 1,200 cr, Ranbaxy doubled costs to Rs 850 cr: ET

The Economic Times research arm, the ET Intelligence Group, surveying more than 1,800 listed companies, has revealed that their legal spend was Rs 21,906 crore ($3.5bn) in the 2013-14 financial year, an increase of more than 17.5 per cent on last ...
 Legally India2 days ago

Podcast (Tamil): Ranbaxy Laboratories

 Hindu Business Line1 week ago Podcast: Ranbaxy Laboratories (English) by Divya Pushkarna  Hindu Business Line1 week ago
Livemint.com

US Department of Justice asks Ranbaxy to submit pricing data

, one of the leading pharma players, said the company has received a civil investigative demand (CID) from the United States Department of Justice. The civil investigative demand is related to the manner in which the company reports pricing data for certain ...
 Myiris1 week ago Ranbaxy receives CID from US Department of Justice  MyIris2 weeks ago Ranbaxy receives CID from US Justice Department  Money Control2 weeks ago Ranbaxy gets civil investigative demand from US on pricing issues  Livemint.com2 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - ranbaxy
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less